On January 22, the World Health Organization (WHO) will start discussing data on the Russian Sputnik V coronavirus vaccine, which may last several days.
The Russian Direct Investment Fund (RDIF) reported that this is a pre-submission review of the Russian Sputnik V vaccine. Vaccine manufacturers submitted an application for certification to the WHO headquarters at the end of last year.
WHO spokeswoman Margaret Harris previously said that discussions on adding the Russian Covid-19 vaccine Sputnik V to the World Health Organization’s list of approved vaccines could take several days.
“The fact that these discussions will take place suggests that we’re at a pretty good stage. But it’s not necessarily the case that these discussions will end on this particular day. Permission to list drugs for emergency use will only be given by experts when they are satisfied with all the data,” she noted.
Kirill Dmitriev, head of RDIF, said that the WHO has received full information on the vaccine but would also like to see the publication of data from the third phase of trials, which may appear as early as next week.
The Sputnik V vaccine has been registered in Argentina, Bolivia, Serbia, Hungary, Algeria, Palestine, UAE, Venezuela, Paraguay, and Turkmenistan under the fast track procedure. The drug is also registered in Russia and Belarus.
The Russian Ministry of Health registered Sputnik V in August 2020; it was developed by the Gamaleya Research Center for EMS. This vaccine was the first in the world to prevent Covid-19.